RxDoctor Payments Data

James Gordon, MD

Infectious Disease · Novi, MINPI 1144239559

Payments from drug & device makers

$950in general payments, 2019–2025

Across 36 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$259
  • Merck$163
  • AbbVie$148
  • Insmed, Inc.$99
  • Ferring Pharmaceuticals Inc.$62
  • Pfizer$49
  • plus $171 from 9 others

What the payments were for

  • Food & beverage$950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$950 in reported general payments places this provider in the 70th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$460,845
Medicare patients
581
Services billed
43,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr19$282,781
BiktarvyBictegrav/Emtricit/Tenofov Ala23$116,783
TriumeqAbacavir/Dolutegravir/Lamivudi21$75,530
Daptomycin85$30,259
Meropenem67$12,624
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium12$4,890
Cefadroxil37$3,486
Rifampin20$2,262
Ethambutol Hcl19$2,201
CeftriaxoneCeftriaxone Sodium64$1,665
Minocycline Hcl22$1,253
Vancomycin Hcl18$1,129
Cefazolin Sodium20$890
Azithromycin25$875
Doxycycline Hyclate22$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$99$282,78119 claims
GileadBiktarvy$17$116,78323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 257 infectious disease providers in Michigan.

Other infectious disease in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →